What America's PBM Crackdown Means for Drug Prices
Washington's campaign against pharmacy benefit managers has put the economics of American medicine under a microscope. What the federal crackdown on pharmacy benefit managers means for drug prices is less certain than the slogans suggest: savings matter only if regulators turn opaque markups and retained rebates into lower spending for patients, rather than merely rearrange money among insurers, pharmacies and drug manufacturers.
For Australian readers, the US system looks unusually indirect. People call a pharmacy a chemist and a prescription a script; for a medicine on the Pharmaceutical Benefits Scheme, the negotiated price and patient co-payment generally apply nationwide, while many chemists can offer a discount. A patient in regional Queensland or Alice Springs may also face stock shortages and transport barriers, with Repatriation PBS and Closing the Gap programs designed to narrow those gaps. Australia has no direct equivalent to the largest integrated PBMs.
| Feature | United States | Australia |
|---|---|---|
| Price negotiation | PBMs bargain for insurers and public programs | Commonwealth negotiates PBS prices |
| Patient charge | Deductibles, coinsurance, premiums and sometimes cash prices | Standard PBS co-payment, with discounts available |
| Oversight | Fragmented across federal and state bodies | National PBS rules and regulators |
| Pharmacy role | Often integrated with the insurer or PBM | Community chemists generally separate from payers |
| Central risk | Hidden spreads, rebates and steering | Access, shortages and remote delivery |
The machinery behind US drug prices
Pharmacy benefit managers are the middlemen insurers and public programs use to negotiate formularies, process claims and reimburse pharmacies. CVS Caremark, Cigna's Evernorth and UnitedHealth's Optum Rx also command pharmacy networks and data systems, giving them huge influence over which medicines patients obtain and on what terms.
That influence creates the dispute. A PBM may claim a discounted price from a manufacturer, charge the plan more and pay the pharmacy less; the difference, called the spread, can become intermediary revenue. Manufacturer rebates add another layer. Patients can benefit through lower premiums or co-payments, but retained rebates are difficult for the public to see.
What the federal campaign is changing
The crackdown is not one sweeping federal law. It combines Federal Trade Commission enforcement, congressional investigations, action by state attorneys general and Medicare rules intended to expose how PBMs use rebates and reimbursement data. Litigation has focused on allegations including inflated reimbursement costs, steering patients towards drugs with larger rebates and using contracting power to delay cheaper generics.
Rebate transparency and pass-through are the central battlegrounds. When a manufacturer pays a rebate, the money should flow through the PBM to the plan and reduce what patients or government pays. Reporting duties give regulators a clearer view of those contracts, while enforcement can challenge a model built on private payment data. The argument is not that PBMs have no legitimate role; it is that they should not use it to obscure prices.
President Donald Trump's focus on drug prices has added pressure, but durability is uncertain. Cases take years, appeals delay remedies and a later administration can redirect enforcement. Durable reform needs audited rebate data, meaningful penalties and a clear line between genuine savings and PBM profit.
Why lower PBM prices may not mean cheaper medicines
Even aggressive PBM reform would not set the launch price of a patented medicine. Manufacturers choose list prices before products reach the market, and insurers negotiate discounts from that starting point. A crackdown can make the final net price more transparent and stop intermediaries retaining part of a discount, but it cannot make an expensive drug cheap if its maker demands a high figure.
Branded medicines are the hardest case because one patent holder may face little competition. Generics are different: multiple suppliers compete and rebates are usually smaller, so inflated reimbursement and steering away from lower-cost products matter more. Improving generic dispensing and fair pharmacy payments could deliver quicker household savings than arguing over a few percentage points of a branded drug's rebate.
Three prices need separating: list price, confidential net price after rebates and what a patient pays. Better PBM accounting may lower insurer spending or premiums without immediately lowering a co-payment. Uninsured patients paying cash may see little benefit if their bill remains tied to list price.
The Australian pharmacy counterpoint
Australia's PBS uses a different design. The Commonwealth negotiates the price of subsidised medicines and patients contribute a nationally defined co-payment; community chemists dispense and claim the subsidy. Private insurers may offer discounts, but they do not usually sit between a patient and a PBS price as a large PBM does. Ownership rules that generally reserve community pharmacies for pharmacists also make the integrated insurer-PBM-pharmacy model less common.
Access is a separate test. A discounted medicine in metropolitan Melbourne means little if a patient near the Northern Territory border cannot obtain it promptly. Shortages, distance and limited staffing can force people to wait, travel or change treatment. National savings must therefore be weighed against rural and remote dispensing conditions, including the role of Aboriginal health services and transport.
Australia is not insulated from US pricing. When manufacturers model revenue from a vast market with negotiated rebates, their launch expectations and prices carried into Australia can change. If American reform rewards transparent net pricing, Australian buyers may gain a cleaner benchmark; if companies simply rebuild the same secret discounts, the effect here will be minimal.
Why Washington still matters in Australia
The first reason is scale. The US buys medicines through public programs and private insurers, so changes in rebate practice can reset manufacturer strategies far beyond the country where they occur. That can influence Australian tenders, private-insurance negotiations and the global price of a new treatment. Transparency would also give Australian regulators and consumer groups a model for checking whether advertised savings are real.
A useful comparative caution comes from coverage of alcohol consumption trends in South Africa. The products differ, but the policy lesson is relevant: regulators must examine commercial responses and public outcomes rather than treating an announcement as proof of success. The same discipline should apply when a lower intermediary fee is presented as a lower household medicine bill.
Measuring whether the crackdown works
The fairest test is not the size of a negotiated rebate, but the combined effect on government spending, insurer premiums and patient out-of-pocket costs after rebates and fees are counted. Strong reform should also make prices easier to compare, increase clinically appropriate generic use, preserve pharmacy networks and reduce steering towards products simply because they earn larger rebates. Otherwise, one participant's savings can become another's costs or worse access.
Watch for measurable change: more rebate data released to regulators, faster generic competition, smaller gaps between list and net prices, and clearer explanations of what patients pay. Implementation matters as much as the ruling. A remedy delayed by appeals or weakened by exemptions can preserve the status quo, while an interim pass-through requirement may deliver benefits sooner.
Turning scrutiny into better drug pricing
Australians can start at the counter. Ask the pharmacist for the PBS price, the concession rate where applicable and whether the chemist offers a discount; request a generic when clinically suitable, and report persistent shortages rather than accepting repeated delays. For a new medicine, compare the PBS and listed prices.
Federal policy should require fuller disclosure of PBM and insurer rebate arrangements, publish meaningful net-price benchmarks and ensure savings reach lower premiums or patient charges. Readers can write to their federal MP to support enforceable pass-through rules and competition safeguards, because a durable remedy needs law, oversight and scrutiny rather than voluntary promises from companies that profit from the system.